Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Bacterial Carbohydrate and Protein Vaccine Research
share announcement

Bacterial Carbohydrate and Protein Vaccine Research

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Adjuvants".

Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 2941

Special Issue Editors

Dr. Vana Spoulou

E-Mail Website
Guest Editor
School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
Interests: immunology vaccination; vaccines immune response; vaccine production
Special Issues, Collections and Topics in MDPI journals
Prof. John Routsias

E-Mail Website
Guest Editor
Department of Microbiology, Athens Medical School, 11527 Athens, Greece
Interests: autoimmunity; autoantibodies; rheumatoid arthritis; systemic lupus erythematosus; inflammation; innate immunity; autoimmune disorders; antinuclear antibodies; immunobiology; autoimmune disease

Special Issue Information

Dear Colleagues,

Vaccines are one of the most cost-effective way to control infectious diseases. Protein vaccines are composed of purified or recombinant proteinaceous antigens from a pathogen, such as a bacterium or virus. In addition to protein antigens, cell surface carbohydrates are widely used as antigenic components of vaccines. Glycoconjugate vaccines are composed of carbohydrate antigens, covalently linked to a carrier moiety, usually a non-toxic protein.

This Special Issue focuses on protein vaccine and bacterial carbohydrate vaccine. Submission of original articles, systematic reviews, short communications, and other types of article on related topics are welcome. Manuscripts will follow standard Journal peer-review practices, and those accepted for publication will appear in the special issue on Bacterial Carbohydrate and Protein Vaccine Research. We look forward to receiving and welcome your contributions.

Dr. Vana Spoulou
Prof. John Routsias
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Protein Vaccine
  • Polysaccharide Vaccine
  • Bacterial Carbohydrates
  • Glycoconjugates
  • Immunogens
  • Peptide Antigens
  • Vaccine Adjuvants

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 1868 KiB  
Article
Multicomponent Vaccines against Group A Streptococcus Can Effectively Target Broad Disease Presentations
by Helen A. Shaw, James Ozanne, Keira Burns and Fatme Mawas
Vaccines 2021, 9(9), 1025; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines9091025 - 15 Sep 2021
Cited by 3 | Viewed by 2268
Abstract
Group A Streptococcus (GAS) is an important global human pathogen, with a wide range of disease presentations, from mild mucosal infections like pharyngitis to invasive diseases such as toxic shock syndrome. The effect on health and mortality from GAS infections is substantial worldwide, [...] Read more.
Group A Streptococcus (GAS) is an important global human pathogen, with a wide range of disease presentations, from mild mucosal infections like pharyngitis to invasive diseases such as toxic shock syndrome. The effect on health and mortality from GAS infections is substantial worldwide, particularly from autoimmune sequelae-like rheumatic heart disease (RHD), and there is currently no licenced vaccine. We investigated protein antigens targeting a broad range of GAS disease presentations as vaccine components in individual and combination formulations. The potency and functional immunity generated were evaluated and compared between groups. Antibodies against all components were found in pooled human IgG (IVIG) and an immune response generated following the subcutaneous immunisation of mice. A combination immunisation showed a reduction in IgG response for SpyCEP but an increase for Cpa and Mac-1 (IdeS). An opsonophagocytosis assay (OPA) showed the killing of GAS with immune sera against M protein and combination groups, with a lower killing activity observed for immune sera against other individual antigens. Specific antigen assays showed functional immunity against SpyCEP and Mac-1 from both individual and combination immunisations, with the activity correlating with antibody titres. However, efficient blocking of the binding activity of Cpa to collagen I and fibronectin could not be demonstrated with immune sera or purified IgG. Our data indicate that combination immunisations, while effective at covering a broader range of virulence factors, can also affect the immune response generated. Further, our results showed that an OPA alone is inadequate for understanding protection from vaccination, particularly when considering protection from immune evasion factors and evaluation of the colonisation leading to pharyngitis. Full article
(This article belongs to the Special Issue Bacterial Carbohydrate and Protein Vaccine Research)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop